公开(公告)号：US20230125604A1

公开(公告)日：2023-04-27

申请号：US17723674

申请日：2022-04-19

Applicant: H. LUNDBECK A/S

Inventor： Maria-Cristina Loomis ,  Leon Garcia-Martinez ,  Benjamin H. Dutzar ,  Daniel S. Allison ,  Katherine Lee Hendrix ,  Ethan W. Ojala ,  Pei Fan ,  Jeffrey T.L. Smith ,  John A. Latham ,  Charlie Karasek ,  Jenny Mulligan ,  Michelle Scalley-Kim ,  Erica Stewart ,  Vanessa Lisbeth Rubin ,  Jens J. Billgren

IPC: C07K14/705 ,  C12N15/09 ,  C12N15/63 ,  A61K39/395 ,  C07K16/28 ,  A61K38/17 ,  A61K38/22 ,  C07K14/47 ,  C07K14/72 ,  C07K16/18 ,  C12N5/07 ,  C07K16/26 ,  C07K16/42 ,  G01N33/68

Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.

公开(公告)号：US11535611B2

公开(公告)日：2022-12-27

申请号：US16955926

申请日：2018-12-19

Applicant: H. Lundbeck A/S

Inventor： Jan Kehler ,  Lars Kyhn Rasmussen ,  Morten Langgård ,  Mikkel Jessing ,  Paulo Jorge Vieira Vital ,  Karsten Juhl ,  Mauro Marigo

IPC: C07D401/14 ,  C07D405/14

Abstract: The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.

公开(公告)号：US11530189B2

公开(公告)日：2022-12-20

申请号：US17195351

申请日：2021-03-08

Applicant: H. Lundbeck A/S ,  THE SCRIPPS RESEARCH INSTITUTE

Inventor： Justin S. Cisar ,  Cheryl A. Grice ,  Todd K. Jones ,  Micah J. Niphakis ,  Jae Won Chang ,  Kenneth M. Lum ,  Benjamin F. Cravatt

IPC: C07D295/205 ,  C07C271/12 ,  C07D317/46 ,  C07D317/58 ,  C07D231/12 ,  C07D231/16 ,  C07D231/56 ,  C07D241/04 ,  C07D471/04 ,  C07D471/10 ,  C07D261/08 ,  C07D487/04 ,  C07D263/32 ,  C07D205/04 ,  C07D491/107 ,  C07D207/14 ,  C07D271/06 ,  C07D307/79 ,  C07D405/14 ,  C07D215/42 ,  C07D213/40 ,  A61P25/22 ,  C07D295/26 ,  C07D213/55 ,  C07D401/04 ,  C07D407/06 ,  C07D413/06 ,  C07C271/10 ,  C07D207/09 ,  C07D213/38 ,  C07D215/46 ,  C07D401/10 ,  C07D403/10 ,  C07D413/10

Abstract: This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.

公开(公告)号：US11464759B2

公开(公告)日：2022-10-11

申请号：US15987449

申请日：2018-05-23

Applicant: H. Lundbeck A/S

Inventor： Kristian Windfeld

IPC: A61K31/4045 ,  A61K31/27 ,  A61K31/445 ,  A61K31/55 ,  A61P25/28 ,  A61K45/06 ,  A61K31/496 ,  A61K31/505

Abstract: The present invention relates to 5-HT6 receptor antagonists for the treatment of Alzheimer's disease where the Alzheimer's disease patient carries one or two ApoE4 alleles comprising administering an effective dose of a 5-HT6 receptor antagonist to improve or augment the effect of an acetylcholinesterase inhibitor.

公开(公告)号：US20220257623A1

公开(公告)日：2022-08-18

申请号：US17386686

申请日：2021-07-28

Applicant: H. Lundbeck A/S

Inventor： Klaus Gjervig Jensen ,  Lisbet Kværnø ,  Morten Jørgensen ,  Martin Juhl

IPC: A61K31/706 ,  A61P25/00 ,  C07D405/12 ,  C07D405/14 ,  A61K31/473

Abstract: The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
Accordingly, the present invention relates to compounds of formula (Id) wherein R1 is H and R2 is selected from one of the substituents (i) and (ii) below; or R1 is selected from one of the substituents (i) and (ii) below and R2 is H; or R1 and R2 are both represented by substituent (i) below; or R1 and R2 are both represented by substituent (ii) below; or R1 is substituent (i) and R2 is substituent (ii); or R1 is substituent (ii) and R2 is substituent (i); wherein * indicates the attachment point; and wherein the carbon atom at the attachment point on substituent (i) is in the S-configuration; or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220220077A1

公开(公告)日：2022-07-14

申请号：US17606303

申请日：2020-05-19

Applicant: H. Lundbeck A/S

Inventor： Morten Jørgensen ,  Erhad Ascic ,  Martin Juhl ,  Klaus Gjervig Jensen ,  Ask Püschl ,  Benny Bang-Andersen

IPC: C07D221/08 ,  C07F9/576

Abstract: The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.

公开(公告)号：US11279682B2

公开(公告)日：2022-03-22

申请号：US16294647

申请日：2019-03-06

Applicant: H. Lundbeck A/S

Inventor： Heidi Lopez de Diego ,  Kim Lasse Christensen ,  Rene Holm ,  Jens Kateb

IPC: C07D295/096 ,  C07D207/28

Abstract: The present invention provides vortioxetine pyroglutamate salt and pharmaceutical compositions comprising said salt.

公开(公告)号：US11111289B2

公开(公告)日：2021-09-07

申请号：US16248284

申请日：2019-01-15

Applicant: H. LUNDBECK A/S

Inventor： Brian Robert Kovacevich ,  Leon F. Garcia-Martinez ,  Katie Olson Anderson ,  Benjamin H. Dutzar ,  Jens J. Billgren ,  John A. Latham ,  Danielle M. Mitchell ,  Patricia Dianne McNeill ,  Nicole M. Janson ,  Maria-Cristina Loomis

IPC: C07K16/18 ,  A61P25/00 ,  C07K16/26 ,  A61K31/485 ,  A61K39/395 ,  A61K49/00 ,  A61K39/00

Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.

公开(公告)号：US20210236634A1

公开(公告)日：2021-08-05

申请号：US17109028

申请日：2020-12-01

Applicant: H. Lundbeck A/S

Inventor： Pekka Kallunki ,  Paul E.G. Kristjansen

IPC: A61K39/395 ,  A61K31/197 ,  A61P25/28 ,  A61P25/16

Abstract: The invention relates to combinational treatment using a monoclonal anti-alpha-synuclein antibody and an additional medicament. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy together with another medicament of the invention.

公开(公告)号：US11059798B2

公开(公告)日：2021-07-13

申请号：US16672870

申请日：2019-11-04

Applicant: H. Lundbeck A/S

Inventor： Morten Jorgensen ,  Peter Hongaard Andersen ,  Klaus Gjervig Jensen

IPC: C07D295/073 ,  C07B59/00 ,  C07D241/04 ,  A61K31/451 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/496 ,  A61K31/519 ,  A61K31/551 ,  A61K31/554 ,  C07C45/61 ,  C07C45/67

Abstract: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.